Prof. Dr. Lieven Annemans
- Prof. Dr. Lieven Annemans has participated in more than 400 health economic evaluations in over 20 countries across a wide spectrum of therapeutic areas. He has also been involved as expert in a large number of Health Technology Assessments (HTAs) and is actively involved in HTA on a European level.
- A unique profile: academic professor, past-president ISPOR, consultant and former pharma executive.
- Highly respected for his vast international and cross-therapeutic experience, Lieven is a much sought-after advisor and educator to health policy makers and the innovative healthcare industry.
- Author of Health economics for non-economists (Pelckmans Pro, 2018).
- The full meaning of QALYs and ICERs, two key measures in cost-effectiveness studies, and how to calculate them
- The challenges with the QALY, especially in particular diseases, and how these can be addressed
- How payers in different countries apply ICER thresholds that are used to select candidates for reimbursement
- The logic and maths of commonly used models that health economists use to simulate treatment outcomes and to predict and compare the cost-effectiveness of different treatments
- The basic principles of a budget impact analysis, which also considers the perspective of the payer’s budget and the choices that have to be made across patient populations
- How health economic insights can add tremendous value to pharma/medtech products throughout their entire lifecycle, from early clinical development up to post-launch
- The supporting training materials (i.e. workbook, exercises, slide printouts and additional readings) will optimize learning retention
- A Learning Coach will address any content-related questions within the scope of this course, with the support of Prof. Dr. Lieven Annemans
Why You Should Take This Course
The Content: Society will only pay for healthcare innovations that have an acceptable cost-effectiveness and budget impact profile. The moment of truth is during pricing & reimbursement negotiations, but the “acceptable” target product profile and supporting health economic evidence must be generated from early clinical development onwards, then successfully negotiated during the market access phases, and finally communicated and proven post-launch in the “real world”. Therefore, all pharma/medtech executives with a thorough understanding of the fundamentals of health economic evaluations will take better decisions that affect the success of pharma/medtech brands in healthcare markets.
The Expert: Prof. Dr. Lieven Annemans, with a background not only in academia but also in pharma, health care policy making and consultancy, has a very strong reputation within the international health economic community. But what qualifies him as being truly exceptional is his talent for explaining complex health economics theory, even to executives without any prior knowledge. His 2-day Health Economics for Non-Health-Economists course that runs since 2009 is very popular and usually fully booked. Lieven’s course gets virtually always 9 or 10/10 as Recommendation Score from participants. Lieven enjoys a wide international reputation across the pharma/medtech industries as a very efficient and high-impact trainer on the fundamentals of health economic evaluations and HTAs.
What is the difference with the 2-day Health Economics for Non-Health-Economists course?
- The 2-day course has more breadth and depth in both theory (lectures) and practice (group work). For instance, the 2-hour module on the “Guidelines for Health Economic Evaluations” is highly valued because of the interactive group work session on a health economic publication.
- In a classroom training, whether face-to-face or virtual, you learn a lot from your industry peers because of the exchange of experiences and ideas and the discussions about issues you face in your function. The (physical) face-to-face version of the 2-day course is obviously most impactful in that respect because the Q&A sessions are very rich and because of the many opportunities for conversations with your peers outside the formal programme.
- Participating in the (physical) face-to-face course gives the opportunity to meet Prof. Dr. Lieven Annemans and discuss your own projects/issues with him during the coffee and lunch breaks.
Agenda of the Online Self-study Programme Basics of Health Economics
MODULE 1 - QALYs & ICERs
The QALY and ICER are two fundamental measures in health economic evaluations. Upon completion of the 1st module, you will fully understand these concepts and the parameters which they are based upon, and be able to calculate them for simple situations. You will also start to understand some of the challenges of using these parameters in cost-effectiveness studies in the context of payer decision making.
- Why health economics, and more specifically: Why do we need health economic evaluations?
- Understanding the QALY, a commonly used measure to quantify the health impact of treatments across diseases
- Examples of utility scores, a key element in QALY calculations, and how changes over time impact on a patient’s QALYs
- Different perspectives of the cost dimension of a new treatment
- Understanding the ICER, a commonly used measure to quantify the cost-effectiveness of treatments across diseases
- Terminology used by health economists for different types of health economic analyses
Lieven will give you 4 exercises on QALY and ICER calculations, which you will need to solve online (via login on our system). Upon completion, you will get access to module 2, at the start of which Lieven explains the solutions.
MODULE 2 - Challenging the QALY and the value of health
Upon completion of the 2nd module, you will understand the challenges of using QALYs and ICERs, which is necessary to fully understand the perspective of the payer and related decision makers in the countries.
You will also understand how payers apply ICER thresholds that are used to select candidates for reimbursement.
- Pros & cons of the different methods used for obtaining the utility scores in QALY calculations
- Direct methods: Time Trade Off and Standard Gamble
- Indirect methods: EuroQoL5D and SF-36
- Shortcomings of the QALY approach, with a focus on the inaccuracies of utility scores in some diseases, and how this is being addressed
- Challenging the ICER thresholds
- Pros & Cons of the different approaches of setting the thresholds: Benchmarking, GDP-based or at the discretion of the payer
- Why disease burden and budget impact need to be considered in deciding what societies are willing to pay for innovations
Lieven will give you 3 exercises on the use of utility scores and ICER thresholds, which you will need to solve online (via login on our system). Upon completion, you will get access to module 3, at the start of which Lieven explains the solutions.
MODULE 3 - Decision models for health economic evaluations
Health economists develop (often complex) models to simulate treatment outcomes and to predict and compare the cost-effectiveness of different treatments, e.g. a new pharmaceutical vs. the standard of care.
Upon completion of the 3rd module, these models will no longer be black boxes for you since Lieven clearly explains their logic and the relatively simple maths applied repeatedly in these models.
- Decision Tree models, most often used for short term treatments
- Understanding the logic and the maths of a simple decision tree for a hypothetical new treatment
- Some real-life examples will illustrate that the same principle is used throughout often rather complex Decision Tree models
- Markov models, most often used for chronic diseases or diseases with sequelae
- Understanding the logic and the maths of a simple Markov model for a hypothetical new treatment
- Several real-life examples will illustrate that the same principle is applied throughout more complex Markov models
- Two key challenges that companies need to be prepared for when facing payers: Model validation and the need for sensitivity analyses to map and manage uncertainty around underlying data
Lieven will give you 2 exercises on the Decision Tree model and 1 on a Markov model, which you will need to solve online (via login on our system). Upon completion, you will get access to module 4, at the start of which Lieven explains the solutions.
MODULE 4 - The cost dimension and budget impact analysis
Decisions related to what costs to include in cost-effectiveness studies are critical since payers will challenge these decisions. Another important element to take into consideration is the impact of a new treatment on healthcare budgets in countries and regions.
Upon completion of the 4th module, you will have a structured overview of the different costs that can and/or should be included in cost-effectiveness studies, and understand the basic principles of a budget impact analysis.
- The cost dimension
- A structured overview of cost categories that can be included in cost-effectiveness studies and how to reflect on those
- The 3-step process for a cost calculation
- Overview of potential data sources
- Understanding the meaning of “discounted results”
- Budget impact analysis
- Thinking from the payer’s budget perspective
- New elements that come into play on top of what is considered in cost-effectiveness studies
- A real-life example in breast cancer that not only illustrates the complexity, but also the necessity for companies to do this seriously
Lieven will give you 2 exercises on the cost dimension and 1 on the budget impact analysis, which you will need to solve online (via login on our system). Upon completion, you will get access to module 5, at the start of which Lieven explains the solutions.
MODULE 5 - Health economic evaluations and clinical trials
Throughout the pharma/medtech industries, R&D is often only loosely connected with functions that interact with healthcare markets (i.e. market access, medical affairs, marketing … ). As a result, products coming out of the R&D pipeline often experience trouble in passing the market access barriers.
Upon completion of the 5th and last module, you will understand how health economic evaluations can help to bridge these 2 “worlds”.
- The tremendous value of health economic insights to pharma/medtech products throughout their entire lifecycle, from early product development onwards
- The conflicting views between clinical trialists and health economists
- How prospective health economic evaluations within clinical trials (also called pragmatic or naturalistic trials) can partly address the problem
- The added value of Real World Evidence to fill the evidence gaps and for demonstrating a products’ value in the real world, e.g. outcomes based contracts
>> Click here if you wish to receive the PDF brochure of this course
This modular online training programme gradually builds up from the fundamental building blocks up to corporate-level strategic decisions that affect all executives contributing to a brand’s success as of early development.
In each module, Prof. Dr. Lieven Annemans clearly explains the theory with simple hypothetical examples, and then illustrates with real-life examples how that theory is applied in the real world. You can get a flavour of Lieven’s impactful presentation style by viewing the above demo with the first 20 mins of his course.
At the end of each module you will need to solve 3 to 4 exercises before you can get access to the next module. This will ensure you sufficiently master the theory to move to the next module.
In case you experience problems with the exercises, or if you have content related questions, a Learning Coach will help you (with the support of Prof. Dr. Lieven Annemans).
The development of this self-study programme benefited from feedback and advice from the following 15 executives, representing a fine cross-section of the international pharmaceutical industry:
|Medical Science Liaison||Amgen||Belgium|
|Global Head of Medical Affairs||Bial||Portugal|
|Commercial Training Lead||Biogen||Switzerland|
|Vice President EU Mid Sized Countries||Daiichi Sankyo||Belgium|
|Market Access Director||Gilead||Italy|
|Head of Chief Medical Office Strategy & Organizational Effectiveness||Merck Group||Germany|
|Executive Director, Business Development and Licensing Europe||MSD||United Kingdom|
|Global Brand Manager||Norgine||United Kingdom|
|Business Franchise Head Ophthalmology||Novartis||Belgium|
|Global Pricing Senior Director||Pfizer||France|
|Head Public Affairs and Communications||Sanofi||Netherlands|
|Director Medical Excellence||Sanofi Pasteur||United States|
|Market Access Manager EU||Santhera Pharmaceuticals||Netherlands|
|Global Pricing Head||UCB||United Kingdom|
|Director of Global Implementation Science||ViiV Healthcare||United Kingdom|
Who Should Take This Course?
Prof. Dr. Lieven Annemans concludes his course with this statement:“Everyone in a (pharma or medtech) company should have knowledge about the basics of health economic evaluations”. That is because all pharma/medtech executives along a product’s life cycle, from early clinical development up to post-launch, will take better decisions for that product if they know the fundamentals of health economic evaluations and can think/act with the payer’s perspectives in mind.
In other words, all executives involved in preclinical and clinical development, regulatory affairs, market access, medical affairs, public affairs, marketing & sales, business development and licensing, business intelligence, market research…, should take this course.
Once we have received payment of the registration fee, you will receive a link to set up your private login account on our website. This will ensure that you have a highly secured access to all course materials, including the exercises and the final test.
A course administrator has been assigned to this self-study programme to ensure a flawless execution of this programme during your learning journey up to the final step, i.e. your certificate.
The self-study programme includes the following course materials and services:
- 5 pre-recorded presentations by Prof. Dr. Lieven Annemans, dated June 2020
- Workbook with the key presentation slides of each module so that you can take notes while watching
- Exercises to be completed in-between the modules
- The full slide deck of each module
- Additional reading: referred publications, useful links and additional reading material
- Your Learning Coach will address any content-related questions you may have during the programme as long as they are within the scope of this course
- The final test which you need to complete to get your course certificate
You can take this course at your own pace within a 10-week timeframe, and you will need to plan +/- 8 hours to complete the whole programme.
Each of the 5 modules consists of a 45-55 mins presentation by Prof. Dr. Lieven Annemans, at the end of which there are several exercises that you need to complete before you get the link to the next module.
You can complete 1 module per day, which means you could theoretically complete the course in a workweek. The service includes a Learning Coach for addressing content-related questions within the scope of this course.
To review a complete module or parts of it, you can either rewind during a presentation or review the complete module until you get access to the next module.
Once you completed a module, you will no longer have access to that module, but you will receive the full slides set.
While this training programme is in the final stages of development, you can already register at the launch fee:
1 270 Euros (excl. VAT; post-launch price is 1 670 Euros).
To ensure we have enough resources for a flawless delivery as of the launch on 15 September 2020, we will limit the number of initial users to 100. We currently already have 22 confirmed registrants.
If you want to be part of the first 100 users, register now. Either go to the registration form via this registration link or via the button in the right column.
Please note that only registrations paid before 31 August 2020 can benefit from the launch fee of 1 270 Euros.
The above-mentioned fee is for a single registration. In order to be able to access the programme via login on our website, you will need to set up a private account on our website with username, password and a Two-fold Authentication (TFA) code. You are not allowed to disclose your login details to any person or otherwise allow any person to access our website using your login information, which would be difficult anyway due to the TFA procedure that continuously updates your personal access code.
If you are interested in this programme for a broader team, please contact Inge Cornelis.